Clinical trials: Cardiovascular Bleeding
Endoleaks
Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair
This study will be a cross-sectional survey of interobserver variability associated with contrast enhanced ultrasound (CEUS) to detect endoleaks using computed tomographic angiography (CTA) as the practice standard.
- Trial name
- AAA CEUS (NCT01005212)
- Testing
- Definity
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- E. Peden, MD
CCM, Cavernoma
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy.
- Conditions
- CCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1
- Trial name
- NCT03652181
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Chicago
Trauma, Hemorrhagic Shock
Control of Major Bleeding After Trauma Study
Bleeding is the most avoidable cause of death in trauma patients. Up to one-third of severely injured trauma patients are found to be coagulopathic and forty percent of the mortality following severe injury is due to…
- Trial name
- COMBAT (NCT01838863)
- Testing
- Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Denver Health and Hospital Authority
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai